Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) FCF Margin (2016 - 2025)

Seres Therapeutics' FCF Margin history spans 10 years, with the latest figure at 689.74% for Q3 2025.

  • For Q3 2025, FCF Margin changed N/A year-over-year to 689.74%; the TTM value through Sep 2025 reached 2417.13%, up 24463912.0%, while the annual FY2023 figure was 99.21%, 314282.0% up from the prior year.
  • FCF Margin for Q3 2025 was 689.74% at Seres Therapeutics, up from 6350.97% in the prior quarter.
  • Across five years, FCF Margin topped out at 689.74% in Q3 2025 and bottomed at 75587.5% in Q4 2023.
  • The 5-year median for FCF Margin is 2922.41% (2022), against an average of 9586.66%.
  • The largest annual shift saw FCF Margin tumbled -7003806bps in 2023 before it soared 6923653bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 740.08% in 2021, then crashed by -650bps to 5549.44% in 2022, then crashed by -1262bps to 75587.5% in 2023, then surged by 92bps to 6350.97% in 2024, then soared by 111bps to 689.74% in 2025.
  • Per Business Quant, the three most recent readings for MCRB's FCF Margin are 689.74% (Q3 2025), 6350.97% (Q4 2024), and 75587.5% (Q4 2023).